Alzheimer's Disease Differential Expression Analysis: Control v. Incipient

Group 1: Austin Cherian, Fadwa Elfeituri, Natalie Ellis, Stephen Payne

HIDS-7003 - Prof. Gusev, Dr. Bhuvaneshwar

What is Alzheimer's Disease

- Alzheimer's disease (AD): The most common form of dementia, affecting millions worldwide.
- A progressive neurodegenerative disorder characterized by:
 - Cognitive decline (e.g., memory loss)
 - Behavioral changes impacting daily life
- Common symptoms:
 - Early: Mild memory loss, word-finding difficulties
 - Progressive: Poor judgment, confusion, apathy, depression



Hallmark Pathologies of AD

- Amyloid-beta (Aβ) plaques: Extracellular protein deposits that interfere with neuronal communication.
- Neurofibrillary tangles (NFTs): Intracellular clumps of hyperphosphorylated tau protein.
- These pathologies contribute to:
 - Neuronal death and Brain tissue loss
 - Disrupted neuronal communication



O1 Introduction about research problem

You can enter a subtitle here if you need it

Research Question

What biological pathways and differentially expressed genes are implicated in early AD pathology?

Methodology

8 Control Group
7 Incipient Group

Molecular Dataset: 43,135 Features **2** Significant Pathways **Clinical Dataset:** 30 Patients 4 DEGs Top Results **Data Source** Sample **Analysis** 15 Patients: **Step 1:** Exploratory Data Analysis

Step 2: Gene Expression Analysis

Step 3: Systems Biology Analysis


Top Pathway Results

Term	Results	Biological Relevance to AD
Wnt signaling pathway	Appeared consistently across databases	Regulates neuronal development, differentiation, and survival [1]
Interleukin-6-Mediated signaling pathway	Appeared consistently across databases	Implicated in inflammatory responses and neuronal apoptosis [5]
Neuronal System	High overlap in Reactome	Major organ system affected by AD [2]
cAMP signaling pathway	High overlap in KEGG	Implicated in neuronal apoptosis [4]
Adherens Jumctiion patthway	Appeared consistently across databases	Supports neuronal connections [3]

Wnt / **\beta-catenin** Signaling Pathway in Brain


Wnt signaling promotes synaptic plasticity and provides neuroprotective effects

- Wnt ligand binds to Frizzled receptors on cell surface
- Destruction complex is inhibited, allowing β-catenin to accumulate in the cytoplasm
- 3. β-catenin translocates to the nucleus and interacts with TCF/LEF to regulate target genes




Wnt / **\beta-catenin** Signaling Pathway in AD

Components of the Wnt $/\beta$ -catenin signaling pathway are often disrupted in AD patients:



Adherens Junction Pathway

[12]




Adherens Junction Pathway in Brain

Tissue Structure

[13]

- Permeability
- Cell Communication

"Down-regulation or deletion of E-cadherin is significantly related to ... poor prognosis."



- VE-cadherin expression reduced
- Binding with fibrinogen-Aβ related to cognitive disorders
- Affects blood flow to brain
- Affects permeability

[3]


- Helps tissue structure of Blood-Brain Barrier
- Barrier = brain permeability
- "damage in the hippocampus, cortex, and cerebrospinal fluid" found in AD cases

[14]

Frizzled-8 (FZD8)

• What is it?

- Member of the Frizzled Receptor family, classified as Wnt receptors that mediate diverse functions in neurons including neurogenesis [23]
- Essential for WNT activation and signal transportation [22]
- Plays a vital role in **stabilizing β-catenin** [21]
- Frizzled–Wnt signalling is important for maintaining a healthy nervous system
 [22]



Frizzled-8 (FZD8)

- Relevance to Alzheimer's Disease:
 - Impaired frizzled receptors function may lead to disruptions in wnt signaling, linked to neuronal damage, synaptic loss, and cognitive decline in Alzheimer's. [25]
- Findings:
 - It was upregulated in **incipient AD** patients with a signed fold change of 1.49
 - P-Value 0.0062
 - CI (0.20, 0.96)
 - This upregulation could indicate an attempt to counteract early AD pathology or reflect underlying changes in Wnt signaling activity

SMAD4 (Mothers Against Decapentaplegic Homolog 4)

Function

- Found on chromosome 18
- Transmits signals from cell surface to nucleus
- Cell growth/division
- Transcription factor
- Tumor suppressor

Relevance to Alzheimer's

- Increased expression associated with AD
- Highly expressed SMAD4 leads to increasing gene transcription of genes associated with Alzheimer's
- SMAD4 alone not significant, found to be significant in TGF-β pathway which is present in both of our chosen pathways

[15]

SMAD4 (Mothers Against Decapentaplegic Homolog 4)

Results: Significant results from two probes

- Upregulated in incipient AD patients compared to controls with a signed fold change of 1.48
 - o P-value: 0.0002
 - o CI: (0.32, 0.80)


- Downregulated in incipient
 AD patients compared to controls with a signed fold change of -1.19
 - o P-value: 0.005
 - o CI: (-0.41, -0.09)

Could indicate different functions of SMAD4 may contribute to AD when over or under expressed

TCF7L1 (Transcription Factor 7 Like 1)

- What is TCF7L1?
 - Member of the T-cell factor/lymphoid enhancer factor (TCF/LEF) family of transcription factors
 - In Wnt signaling pathway, it acts as a transcriptional activator upon β-catenin accumulation [1]
- Relevance to Alzheimer's Disease:
 - TCF7L1 is significantly reduced in hippocampus of AD patients [10]

Reduced impairment and cognitive decline



TCF7L1 (Transcription Factor 7 Like 1)


Results:

- We found TCF7L1 to be upregulated in incipient AD patients compared to controls with a signed fold change of 1.39
 - o P-value: 0.009
 - o CI: (0.14, 0.81)
- Might suggest a compensatory response to early neurodegeneration, though further research is needed to confirm this

CSNK2A2 (Casein Kinase 2 Alpha 2)

- What is CSNK2A2
 - Constitutively active serine/threonine kinase
 - Member of protein kinases that regulates cell growth,
 DNA repair, and apoptosis inhibition.
 - Role In Wnt Signaling Pathway [19]:
 - CK2 stabilizing β-catenin, a critical component for activating Wnt target genes
- Relevance to Alzheimer's Disease
 - CK2 levels increased within the hippocampus and temporal cortex of AD patients [20]





CSNK2A2 (Casein Kinase 2 Alpha 2)

Results:

- We found CSNK2A2 to be down regulated in incipient AD patients compared to controls with a signed fold change of -1.40
 - P-value: 0.007
 - o CI: (-0.81, -0.17)
- Might suggest compensatory mechanism to hyperphosphorylation of Tau by CK2 but need more research

Conclusions

- FZD8 gene was found to be upregulated, however, limited research links it directly to AD. The majority indicate that it may play a role in several types of cancer rather than Alzheimer's
- TCF7L1 results contradict literature, suggesting further research on compensatory mechanisms in early AD patients
- SMAD4 showed both downregulation and upregulation in some of the incipient group

Future Improvements

Expanded Cohort for Wnt/Adherens Pathway Biomarkers

 To validate the identified genes as biomarkers in larger and diverse patient cohorts.

Longitudinal Analysis of Wnt and Adherens Pathways

 To observe the progressive changes in the pathways from early to advanced stages of AD. This could reveal critical stages where pathway dysfunction accelerates AD progression.

Investigate Compensatory Mechanisms

 Exploring additional cohorts could help confirm or clarify the reasons behind the upregulation and downregulation of the genes, potentially revealing compensatory responses to neurodegeneration in the early stages of Alzheimer's disease.

References

- 1. Nagu, P., Sharma, V., Behl, T. *et al.* (2022). Molecular Insights to the Wnt Signaling During Alzheimer's Disorder: a Potential Target for Therapeutic Interventions. *J Mol Neurosci* 72, 679–690. https://doi.org/10.1007/s12031-021-01940-5
- 2. Yu, H., Ding, Y., Wei, Y., Dyrba, M., Wang, D., Kang, X., Xu, W., Zhao, K., Liu, Y., & for the Alzheimer's Disease Neuroimaging Initiative (2023). Morphological connectivity differences in Alzheimer's disease correlate with gene transcription and cell-type. *Human Brain Mapping*, 44(18), 6364–6374. https://doi.org/10.1002/hbm.26512
- 3. Zenaro E., Piacentino, G., Constantin, G. (2017). The blood-brain barrier in Alzheimer's disease. *Neurobiology of Disease* 107,41-56. https://doi.org/10.1016/j.nbd.2016.07.007
- 4. Li, H., Yang S., Wul, J. et al. (2017).cAMP/PKA signaling pathway contributes to neuronal apoptosis via regulating IDE expression in a mixed model of type 2 diabetes and Alzheimer's disease. *J Cellular Biochemistry* 119(2), 1616–1626. https://doi.org/10.1002/jcb.26321
- 5. Kaurani, L., Pradhan R., Schroder, S. *et al.* (2024). A role for astrocytic miR-129-5p in Frontotemporal Dementia. *bioRxiv*. https://doi.org/10.1101/2024.04.15.589528
- 6. Inestrosa, N., Varela-Nallar, L. (2014). Wnt signaling in the nervous system and in Alzheimer's disease, *Journal of Molecular Cell Biology*, 6(1), 64–74. https://doi.org/10.1093/jmcb/mjt051
- 7. Jia, L., Piña-Crespo, J. & Li, Y. (2019).Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer's disease. *Mol Brain* 12, 104. https://doi.org/10.1186/s13041-019-0525-5
- 8. Chen, Jianyong et al. (2006). Activity-dependent Synaptic Wnt Release Regulates Hippocampal Long Term Potentiation. Journal of Biological Chemistry, 281(17), 11910 11916. https://www.ibc.org/article/S0021-9258(19)46699-4/fulltext
- 9. Sharma, V., Sharma, P. & Singh, T.G. (2024). Wnt signalling pathways as mediators of neuroprotective mechanisms: therapeutic implications in stroke. *Mol Biol Rep* 51, 247 https://doi.org/10.1007/s11033-023-09202-w
- 10. Riise, J., Plath, N., Pakkenberg, B. *et al.* (2015). Aberrant Wnt signaling pathway in medial temporal lobe structures of Alzheimer's disease. *J Neural Transm* 122, 1303–1318. https://doi.org/10.1007/s00702-015-1375-7

References

- 12. Adherens Junction Homo Sapiens (human). KEGG PATHWAY: Adherens junction Homo sapiens (human). (n.d.). https://www.genome.jp/pathway/hsa04520
- 13. Adherens Junction pathway. Bosterbio. (n.d.). https://www.bosterbio.com/pathway-maps/adhesion-ecm-cytoskeleton/adherens-junction-pathway
- 14. Sharma, C., Woo, H., & Kim, S. R. (2022). Addressing Blood–Brain Barrier Impairment in Alzheimer's Disease. Biomedicines, 10(4), 742. https://doi.org/10.3390/biomedicines10040742
- 15. U.S. National Library of Medicine. (2020, February 1). Smad4 Gene. MedlinePlus. https://medlineplus.gov/genetics/gene/smad4/
- 16. Burton, T., Liang, B., Dibrov, A., & Amara, F. (2002). Transforming growth factor-β-induced transcription of the alzheimer β-amyloid precursor protein gene involves interaction between the CTCF-complex and Smads. Biochemical and Biophysical Research Communications, 295(3), 713–723. https://doi.org/10.1016/s0006-291x(02)00725-8
- 17. What is Alzheimer's? [Internet]. Alzheimer's Disease and Dementia. 2024 [cited 2024 Nov 6]. Available from: https://www.alz.org/alzheimers-dementia/what-is-alzheimers
- 18. https://www.facebook.com/NIHAging. What Is Alzheimer's Disease? [Internet]. National Institute on Aging. 2021 [cited 2024 Nov 6]. Available from: https://www.nia.nih.gov/health/alzheimers-and-dementia/what-alzheimers-disease
- 19. Dominguez I, Sonenshein GE, Seldin DC. Protein Kinase CK2 in Health and Disease. Cellular and Molecular Life Sciences [Internet]. 2009 Apr 23 [cited 2024 Nov 6];66(11-12):1850–7. Available from: https://link.springer.com/article/10.1007/s00018-009-9153-z
- 20. Andrea, Tjado H. J. Morrema, Gerritsen WH, Elise, Hripsime Snkhchyan, Riet Hilhorst, et al. Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer's disease pathology. Journal of Neuroinflammation [Internet]. 2016 Jan 6 [cited 2024 Nov 6];13(1). Available from: https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-015-0470-x

References

- 21. GeneCards. (n.d.). FZD8 Gene GeneCards | FZD8 Protein | FZD8 Antibody. FZD8 Gene GeneCards | FZD8 Protein | FZD8 Antibody
- 22. ScienceDirect. (n.d.). Frizzled receptors (FZD) play multiple cellular roles in development, in diseases, and as potential therapeutic targets. Frizzled receptors (FZD) play multiple cellular roles in development, in diseases, and as potential therapeutic targets ScienceDirect
- 23. Frontiers. (n.d.). A role for Frizzled and their post-translational modifications in the mammalian central nervous system. Frontiers

 | A Role for Frizzled and Their Post-Translational Modifications in the Mammalian Central Nervous System
- 24. Wang, Y., Lin, C., Zhao, Z., He, X., & Zhang, Z. (2023). Exploring the impact of oxidative stress on neurodegeneration: Mechanisms and therapeutic strategies in Alzheimer's disease. Frontiers in Neuroscience, 17, Article 10527795.

 https://doi.org/10.3389/fnins.2023.10527795
- 25. Höglinger, G. U., & Prigione, A. (2008). Neurodegenerative disease as the progressive loss of structure and function of neurons, including death of neurons. *Progress in Neurobiology*, *85*(2), 269–279. https://doi.org/10.1016/j.pneurobio.2008.03.004

Thank You